<unk>  is an antineoplastic agent that is FDA approved for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include anemia, thrombocytopenia, neutropenia, leukopenia, nausea, diarrhea, vomiting, constipation, fatigue, pyrexia, cough, dyspnea, somnolence, dizziness, peripheral neurologic disorders, hypoesthesia, headache, and paresthesia.
Nelarabine
Vidarabine
Fludarabine 
Clofarabine
Floxuridine
Idoxuridine
Mafosfamide
Dihydroergocristine